Dizal (Jiangsu) Pharmaceutical Co Ltd Class A 688192
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 688192 is a good fit for your portfolio.
News
-
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
-
FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Trading Information
- Previous Close Price
- CNY 42.51
- Day Range
- CNY 40.30–43.00
- 52-Week Range
- CNY 24.82–54.58
- Bid/Ask
- CNY 40.66 / CNY 40.78
- Market Cap
- CNY 16.95 Bil
- Volume/Avg
- 2.8 Mil / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 96.76
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 581
- Website
- http://www.dizalpharma.com
Comparables
Valuation
|
Metric
|
688192
|
603896
|
301281
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 22.46 | 54.64 |
Price/Book Value | 24.33 | 2.44 | 2.34 |
Price/Sales | 96.76 | 6.72 | 6.29 |
Price/Cash Flow | — | 18.79 | 139.15 |
Price/Earnings
688192
603896
301281
Financial Strength
|
Metric
|
688192
|
603896
|
301281
|
|---|---|---|---|
Quick Ratio | 1.59 | 3.29 | — |
Current Ratio | 1.80 | 3.64 | — |
Interest Coverage | −100.52 | 12.27 | — |
Quick Ratio
688192
603896
301281
Profitability
|
Metric
|
688192
|
603896
|
301281
|
|---|---|---|---|
Return on Assets (Normalized) | −66.38% | 7.77% | 3.70% |
Return on Equity (Normalized) | −99.78% | 11.42% | 4.08% |
Return on Invested Capital (Normalized) | −78.11% | 7.56% | 4.08% |
Return on Assets
688192
603896
301281
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Chvpxkczt | Vpqgy | $77.1 Bil | |
MKKGY
| Merck KGaA ADR | Vydqlrzy | Fvnpkyn | $72.9 Bil | |
HLN
| Haleon PLC ADR | Gyysrbbn | Qlphl | $37.5 Bil | |
VTRS
| Viatris Inc | Fqbyybkq | Dxsk | $13.3 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Tpwdxkgw | Wqgc | $11.7 Bil | |
CTLT
| Catalent Inc | Bktdsnkv | Qbxjd | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Qbxkfnpj | Xqpmt | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Llrfwbtbj | Xxh | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Rcvwxqwb | Zgwnxd | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Pcxrzbzkp | Nnlp | $3.0 Bil |